Dr. Mabel Mardones, MD

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.